Background：May-Thurner syndrome is an uncommon disease entity in which the left common iliac vein is compressed by the right common iliac artery, with the subsequent development of deep vein thrombosis and chronic venous insufficiency. Herein, our experience on the treatment of extensive iliofemoral deep venous thrombosis due to May-Thurner syndrome, using endovascular techniques, is reported. Methods：Twenty-one symptomatic patients, 8 men and 13 women, with a mean age of 51 years, were referred for treatment. Eighteen of these patients were treated with catheter-guided thrombolysis, but three, with short segment involvement, did not require thrombolysis. After completion of the thrombolytic therapy, the residual venous narrowing was treated by balloon angioplasty and/or self-expandable stent placement. Patients were then followed-up by clinic visits and venography. Results：The mean total dose of urokinase and duration of infusion were 4.28±1.89 million units and 72±35 hours, respectively. Eighteen of the 21 patient received stent deployments. The mean diameter of the stents was 12.9±2.0 mm. Initial technical success, with immediate symptom resolution, was achieved in 20 of the 21 patients (95%). Among the patients who received stent implantation, two had recurrent thrombotic occlusion during the follow-up period. (mean 10.8 months) ; all three patients who did not receive stent implantation had recurrent thromboses There were no major bleeding complications, with the exception of one patient who developed a retroperitoneal hematoma. Conclusions：Catheter-guided thrombolysis and angioplasty with stent implantation are safe and effective for the treatment of May-Thurner syndrome. (Korean Circulation J 2004 ; 34 (7) : 655-659) 
Introduction
In 1956, May and Thurner first described a spur-like formation of the left common iliac vein in 22% of autopsies. 1) Chronic pulsatile compression of the left common iliac vein, between the right common iliac artery and the lumbar vertebral body, may induce excessive local intimal proliferation, resulting in impaired venous return and massive venous thrombosis. 2) Usually, these patients present with left leg edema, pain or deep vein thrombosis. Because of the chronic physical compression by the right common iliac artery and the large size of the thrombus that develops at the iliac vein, anticoagulation alone is usually ineffective in resolving the deep vein thrombosis and the subsequent prevention of pulmonary embolisms. Previous reports have shown anticoagulation alone, and a thrombectomy combined with prospective anticoagulation, to have rethrombosis rates of up to 73% in patients with a venous spur. 3) Therefore, corrective treatment is indicated to prevent the development of a pulmonary embolism and the long-term complications of post-thrombotic syndrome, including chronic leg edema, pain, hyperpigmentation and skin ulcers. Recently, catheter-directed thrombolysis and endovascular angioplasty with stents have been used to treat DVT in these patients. Herein, our experience and treatment efficacy of endovascular venous angioplasty in patients with deep vein thrombosis due to May-Thurner syndrome is reported. and performed for 6 months. A venogram was performed 1 week after the procedure, immediately before discharge and 6 months after the procedure, to assess the patency rate.
Methods

Results
Out of the 21 patients, there were 8 males and 13 female, with an average age of 51 years. Three of the patients demonstrated complications due to pulmonary thromboembolism on a lung perfusion scan and a further 3 did not undergo catheter guided thrombolysis due to the short length of their lesion. The average infusion rate and total dose of urokinase were 92000±30000 IU/hr and 4,280,000±1890000 IU, respectively, with a total infusion time of 72±35 hours. For the treatment of residual stenosis, balloon angioplasty alone was performed on 3 patients, and stent implantation on 18. Wallstent However, the use of systemic thrombolytic therapy is limited by the possibility of severe bleeding complications, which make it contraindicatory for patients at a high risk of deep vein thrombosis formation, such as in pregnancy, surgery and cerebrovascular disease. 10)11) Localized thrombolytic therapy is commonly being performed to decrease the risk of major bleeding. Theoretically, local infusion of thrombolytic agents at the site of thrombotic occlusion maximizes the therapeutic effect while minimizing the risk of major bleeding. The successful treatment of deep vein thrombosis with local thrombolytic therapy has already been shown. 12)13) Urokinase is used in our catheter laboratory because of its lower cost and lower rate of bleeding complications compared to t-PA.
All the patients in the study group showed successful recanalization, with only one case of major bleeding resulting in a retroperitoneal hematoma, which resolved uneventfully.
The popliteal vein is the usual site of access used by us, with the internal jugular vein (n=2) and right common femoral vein (n=1) being the other sites used. Use of these sites entails passing catheters in a retrograde fashion, so infusion of the thrombolytic drug may be less effective. Direct puncture of the left common femoral vein is inadvisable as thrombolysis or intervention will some-times involve the access site. In 6 cases of this study, the left common femoral vein had a thrombus and required stent insertion. Therefore, the common femoral vein is used as the access site only when the involved site is short and limited within the femoral vein.
The rationale for angioplasty with stent implantation in residual stenosis is that the implant of a stent is effective therapy for a venous obstruction 14) and superior to balloon dilatation alone. 15) The possible problem of valve destruction by the stents, and the subsequent development of venous insufficiency, does not apply to femoral veins due to the absence of valves in the femoral veins.
Complete resolution of the residual stenosis may not be possible with balloon angioplasty, which may result in higher risk of rethrombosis. In fact, all 3 patients who underwent balloon angioplasty alone showed restenosis and rethrombosis, which reemphasizes the importance of complete resolution of the residual stenosis. This was demonstrated by the fact that only 2 of the 17 patients showed thrombus formation at the site of stent implantation at follow-up. Because of the inherent thrombogenicity of metallic stents before endothelization and the high risk of recurrent venous thrombosis, all the patients received standard prophylactic treatment with coumadine for 6 months. It is our belief the duration of treatment is adequate unless there are associated conditions requiring prolonged or indefinite anticoagulation.
There was a single case of major bleeding complication that resulted in a retroperitoneal hematoma, which resolved spontaneously in 13 days. After the procedure, all 21 patients showed no evidence of newly developed pulmonary embolism in the follow-up lung perfusion scans performed within 7 days of the procedure. This study has demonstrated the safety of local catheter guided thrombolysis and stenting, with minimal risk of major bleeding complications and iatrogenic embolism during the procedure. This study has shown excellent immediate results and patency rates, with minimal complications, using localized catheter-guided thrombolysis plus angioplasty with stent implantation. Further studies will be needed to demonstrate the long term patency rate in a larger population of patients.
